Coherus to Present at Investor Conferences
Analysis based on 6 articles · First reported Aug 31, 2026 · Last updated Aug 31, 2026
The announcement is routine and unlikely to materially affect Coherus's stock price. Participation in investor conferences provides visibility and an opportunity to communicate strategy, but no financial or clinical updates were disclosed.
Coherus Oncology, Inc. (NASDAQ: CHRS) announced on August 31, 2026, that it will participate in three upcoming investor conferences in New York City: the Baird 2026 Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. The company will present via webcast and offer one-on-one meetings with management. Coherus is a commercial-stage oncology company focused on its PD-1 inhibitor LOQTORZI and pipeline candidates Tagmokitug and Casdozokitug.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard